Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Vicore Pharma Holding

10.36 SEK

+3.70 %

Less than 1K followers

VICO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+3.70 %
-4.78 %
-13.95 %
+9.17 %
+22.60 %
+37.58 %
-55.63 %
-47.03 %
+105.15 %

Vicore Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for pulmonary and cardiovascular diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
2.92B SEK
Turnover
5.14M SEK
Revenue
109.35M
EBIT %
-177.59 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/2
2026

Annual report '25

6/5
2026

General meeting '26

6/5
2026

Interim report Q1'26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release11/28/2025, 8:00 AM

Ökning av antalet aktier och röster i Vicore Pharma

Vicore Pharma Holding
Regulatory press release11/28/2025, 8:00 AM

Increase in number of shares and votes in Vicore Pharma

Vicore Pharma Holding
Regulatory press release11/27/2025, 9:04 AM

Finansinspektionen: Flaggningsmeddelande i Vicore Pharma Holding AB

Vicore Pharma Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/20/2025, 7:00 AM

Vicore presenterar på DNB Carnegie Nordic Healthcare Conference

Vicore Pharma Holding
Press release11/20/2025, 7:00 AM

Vicore to present at the DNB Carnegie Nordic Healthcare Conference

Vicore Pharma Holding
Press release11/17/2025, 7:00 AM

Vicore to present at the Jefferies Global Healthcare Conference in London

Vicore Pharma Holding
Press release11/17/2025, 7:00 AM

Vicore presenterar på Jefferies Global Healthcare Conference i London

Vicore Pharma Holding
Regulatory press release11/14/2025, 10:49 AM

Finansinspektionen: Flaggningsmeddelande i Vicore Pharma Holding AB

Vicore Pharma Holding
Regulatory press release11/13/2025, 12:50 AM

Vicore Pharma announces successful execution of a directed share issue of approximately USD 48 million (approximately SEK 455 million)

Vicore Pharma Holding
Regulatory press release11/13/2025, 12:50 AM

Vicore Pharma har framgångsrikt genomfört en riktad nyemission om cirka 48 miljoner USD (cirka 455 miljoner kronor)

Vicore Pharma Holding
Regulatory press release11/12/2025, 4:31 PM

Vicore Pharma intends to carry out a directed share issue

Vicore Pharma Holding
Regulatory press release11/12/2025, 4:31 PM

Vicore Pharma avser att genomföra en riktad nyemission av aktier

Vicore Pharma Holding
Press release11/5/2025, 7:30 AM

Vicore presenterar vid kommande investerarkonferenser

Vicore Pharma Holding
Press release11/5/2025, 7:30 AM

Vicore to Present at Upcoming Investor Conferences

Vicore Pharma Holding
Regulatory press release11/5/2025, 7:00 AM

Delårsrapport juli-september 2025

Vicore Pharma Holding
Regulatory press release11/5/2025, 7:00 AM

Interim Report July – September 2025

Vicore Pharma Holding
Regulatory press release11/3/2025, 8:00 AM

Vicore offentliggör valberedningen inför årsstämman 2026

Vicore Pharma Holding
Regulatory press release11/3/2025, 8:00 AM

Vicore announces the Nomination Committee for the 2026 Annual General Meeting

Vicore Pharma Holding
Press release9/30/2025, 6:30 AM

Buloxibutid erhåller särläkemedelsstatus i Japan för behandling av idiopatisk lungfibros

Vicore Pharma Holding
Press release9/30/2025, 6:30 AM

Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.